2024
DOI: 10.33713/egetbd.1450605
|View full text |Cite
|
Sign up to set email alerts
|

Global DNA Methylation analysis of imatinib resistant and sensitive K562 cells

Yalda Hekmatshoar

Abstract: OBJECTIVE: Chronic myeloid leukemia (CML) is a hematological disease which is known by the presence of Philadelphia chromosome (Ph+). BCR-ABL protein is expressed by Ph+ chromosome, represents constant increased tyrosine kinase activity. Imatinib (IMA) is a tyrosine kinase inhibitor (TKI) which is utilized as a first line treatment in CML. Emergence of IMA resistance at some point of therapy leads to treatment failure. DNA methylation is considered to be the most stable epigenetic change and several studies ha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 22 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?